Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-CD19 CAR NK cells for relapsed or refractory B-NHL
NCT04639739Phase 1Unknown
- Sponsor
- Xinqiao Hospital
- Start
- Dec 2020
- Primary completion
- Dec 2021
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of anti-CD19 CAR NK in B-cell non-Hodgkin lymphoma, sponsored by Xinqiao Hospital. Primary endpoints: Incidence of dose limiting toxicity at 4 weeks and Incidence and severity of Adverse Events and Serious Adverse Events at 24 months. Status: unknown.
02
Drugs
anti-CD19 CAR NK
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT04639739.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04639739.